BRPI0519471A2 - formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparo - Google Patents
formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparoInfo
- Publication number
- BRPI0519471A2 BRPI0519471A2 BRPI0519471-7A BRPI0519471A BRPI0519471A2 BR PI0519471 A2 BRPI0519471 A2 BR PI0519471A2 BR PI0519471 A BRPI0519471 A BR PI0519471A BR PI0519471 A2 BRPI0519471 A2 BR PI0519471A2
- Authority
- BR
- Brazil
- Prior art keywords
- controlled release
- oral administration
- preparation
- diabetic drugs
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
FORMULAÇçO COMPLEXA DE LIBERAÇçO CONTROLADA PARA ADMINISTRAÇçO ORAL DE MEDICAMENTOS PARA DIABÉTICOS E MÉTODO PARA O SEU PREPARO. Uma formulação de combinação de liberação controlada para administração oral compreendendo: a) uma porção de liberação controlada contendo metformina ou um sal farmaceutícamente aceitável seu como um ingrediente ativo e uma combinação de um óxido de polietileno e uma goma natural como um veículo para liberação controlada; e b) uma porção de liberação rápida contendo um medicamento baseado em sulfoniluréia para tratar diabetes como um ingrediente ativo revestido na porção de liberação controlada é útil para o tratamento de diabetes, por ele ser capaz de manter uma concentração efetiva dos medicamentos no sangue num nível constante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040117781A KR100760430B1 (ko) | 2004-12-31 | 2004-12-31 | 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법 |
PCT/KR2005/004609 WO2006071078A1 (en) | 2004-12-31 | 2005-12-28 | Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0519471A2 true BRPI0519471A2 (pt) | 2009-01-27 |
Family
ID=36615157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0519471-7A BRPI0519471A2 (pt) | 2004-12-31 | 2005-12-28 | formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparo |
Country Status (14)
Country | Link |
---|---|
US (1) | US20100003289A1 (pt) |
EP (1) | EP1830820A4 (pt) |
JP (1) | JP2008526733A (pt) |
KR (1) | KR100760430B1 (pt) |
CN (1) | CN101094657B (pt) |
AU (1) | AU2005320362B2 (pt) |
BR (1) | BRPI0519471A2 (pt) |
CA (1) | CA2592173C (pt) |
HK (1) | HK1111902A1 (pt) |
IL (1) | IL183982A (pt) |
MX (1) | MX2007008033A (pt) |
NZ (1) | NZ556775A (pt) |
RU (1) | RU2355386C2 (pt) |
WO (1) | WO2006071078A1 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EA015687B1 (ru) | 2006-05-04 | 2011-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Полиморфы |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
TWI421102B (zh) * | 2007-07-19 | 2014-01-01 | Takeda Pharmaceutical | 固態製劑 |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
KR101512386B1 (ko) * | 2008-04-08 | 2015-04-17 | 제이더블유중외제약 주식회사 | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
BRPI0919288A2 (pt) | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
TWI508965B (zh) | 2008-12-23 | 2015-11-21 | Boehringer Ingelheim Int | 有機化合物的鹽形式 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
EP2228066A1 (en) | 2009-03-03 | 2010-09-15 | LEK Pharmaceuticals d.d. | Pharmaceutical compositions of sulphonylurea-based active pharmaceutical ingredient with excellent dissolution properties |
WO2011008053A2 (ko) * | 2009-07-17 | 2011-01-20 | 한올바이오파마주식회사 | N,n-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제 |
WO2011008054A2 (ko) * | 2009-07-17 | 2011-01-20 | 한올바이오파마주식회사 | N,n-디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제 |
JP5662453B2 (ja) * | 2009-10-02 | 2015-01-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物の治療上の使用 |
ES2760917T3 (es) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina |
KR101193495B1 (ko) * | 2010-02-01 | 2012-10-23 | 한미사이언스 주식회사 | 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물 |
PT2566469T (pt) | 2010-05-05 | 2023-01-10 | Boehringer Ingelheim Int | Terapia de combinação |
EP2585101A1 (en) | 2010-06-24 | 2013-05-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
PL2731947T3 (pl) | 2011-07-15 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
KR102240429B1 (ko) | 2013-05-06 | 2021-04-15 | 한미약품 주식회사 | 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형 |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
KR101526825B1 (ko) * | 2014-12-23 | 2015-06-08 | 주식회사 한독 | 당뇨병 치료용 약제학적 조성물 |
CN105878256B (zh) * | 2015-01-05 | 2019-10-22 | 合肥立方制药股份有限公司 | 含有盐酸二甲双胍和格列美脲的控释制剂及其制备方法 |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
US10866140B2 (en) * | 2017-04-20 | 2020-12-15 | Shimadzu Corporation | Spectrophotometer |
KR102598696B1 (ko) * | 2022-11-18 | 2023-11-06 | 고덕상 | 미네랄 촉매제를 이용한 건축자재 제조방법 |
KR102598693B1 (ko) * | 2022-11-18 | 2023-11-06 | 고덕상 | 미네랄 촉매제를 이용한 생활용품 제조방법 |
KR102598700B1 (ko) * | 2022-11-18 | 2023-11-07 | 고덕상 | 미네랄 촉매제를 이용한 그릇 제조방법 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3320583A1 (de) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung |
SE9403158D0 (sv) * | 1994-09-21 | 1994-09-21 | Pharmacia Ab | New use of prostaglandins |
PT998271E (pt) * | 1997-06-06 | 2005-10-31 | Depomed Inc | Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis |
CN1203846C (zh) | 1998-03-19 | 2005-06-01 | 布里斯托尔-迈尔斯斯奎布公司 | 高溶解性药物的双相控释递送系统和方法 |
EP0974356B1 (en) * | 1998-07-15 | 2003-09-24 | Merck Sante | Tablets comprising a combination of metformin and glibenclamide |
IL150568A0 (en) * | 2000-02-04 | 2003-02-12 | Depomed Inc | A controlled release oral drug dosage form |
CA2450957A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
WO2003026637A2 (en) * | 2001-09-28 | 2003-04-03 | Sun Pharmaceutical Industries Limited | Dosage form for treatment of diabetes mellitus |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
WO2004045622A1 (en) * | 2002-11-15 | 2004-06-03 | Ranbaxy Laboratories Limited | Pharmaceutical dosage forms of biguanide-sulfonylurea combinations |
EP1841414A1 (en) * | 2003-12-31 | 2007-10-10 | Alpharma, Inc. | Rosiglitazone and metformin formulations |
-
2004
- 2004-12-31 KR KR1020040117781A patent/KR100760430B1/ko active IP Right Grant
-
2005
- 2005-12-28 US US11/722,560 patent/US20100003289A1/en not_active Abandoned
- 2005-12-28 CN CN200580045285XA patent/CN101094657B/zh not_active Expired - Fee Related
- 2005-12-28 MX MX2007008033A patent/MX2007008033A/es active IP Right Grant
- 2005-12-28 RU RU2007129155/15A patent/RU2355386C2/ru not_active IP Right Cessation
- 2005-12-28 EP EP05823877A patent/EP1830820A4/en not_active Withdrawn
- 2005-12-28 JP JP2007549261A patent/JP2008526733A/ja active Pending
- 2005-12-28 WO PCT/KR2005/004609 patent/WO2006071078A1/en active Application Filing
- 2005-12-28 NZ NZ556775A patent/NZ556775A/en not_active IP Right Cessation
- 2005-12-28 CA CA2592173A patent/CA2592173C/en not_active Expired - Fee Related
- 2005-12-28 AU AU2005320362A patent/AU2005320362B2/en not_active Ceased
- 2005-12-28 BR BRPI0519471-7A patent/BRPI0519471A2/pt active Search and Examination
-
2007
- 2007-06-17 IL IL183982A patent/IL183982A/en not_active IP Right Cessation
-
2008
- 2008-06-18 HK HK08106750.9A patent/HK1111902A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1830820A1 (en) | 2007-09-12 |
HK1111902A1 (en) | 2008-08-22 |
KR20060077812A (ko) | 2006-07-05 |
RU2007129155A (ru) | 2009-02-10 |
NZ556775A (en) | 2009-08-28 |
MX2007008033A (es) | 2007-08-22 |
US20100003289A1 (en) | 2010-01-07 |
CN101094657B (zh) | 2012-01-04 |
IL183982A (en) | 2013-07-31 |
CA2592173C (en) | 2011-08-02 |
IL183982A0 (en) | 2007-10-31 |
AU2005320362B2 (en) | 2009-02-26 |
KR100760430B1 (ko) | 2007-10-04 |
RU2355386C2 (ru) | 2009-05-20 |
JP2008526733A (ja) | 2008-07-24 |
AU2005320362A1 (en) | 2006-07-06 |
WO2006071078A1 (en) | 2006-07-06 |
EP1830820A4 (en) | 2012-10-24 |
CA2592173A1 (en) | 2006-07-06 |
CN101094657A (zh) | 2007-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0519471A2 (pt) | formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparo | |
JP6568519B2 (ja) | 医療用被覆器具 | |
RU2355387C2 (ru) | Трансдермальный гранисетрон | |
AU2020201256B2 (en) | Hypertonic antimicrobial therapeutic compositions | |
BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
HRP20100434T1 (hr) | Postupci liječenja zaraze virusom hiv | |
BRPI0415649A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
BRPI0707235B1 (pt) | formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual | |
JP2008519047A5 (pt) | ||
KR900015730A (ko) | 정신장해 치료방해 | |
CN102711742A (zh) | 具有纳米粒子溶液和纳米粒子悬浮液的局部用医药制剂以及用其治疗急性和慢性疼痛的方法 | |
AU2014318702A1 (en) | Hypertonic antimicrobial therapeutic compositions | |
RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
WO2021202245A1 (en) | Viral treatment regimens | |
Jayant et al. | Nanotechnology for the treatment of NeuroAIDS | |
BRPI0607172A2 (pt) | método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos | |
ATE361065T1 (de) | Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes | |
BR0115390A (pt) | Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica | |
JP2010538066A5 (pt) | ||
WO2014159060A1 (en) | Method of treating infections, diseases or disorders of nail unit | |
CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
JP2001316293A5 (pt) | ||
AR030551A1 (es) | Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante | |
RU2790837C2 (ru) | Спрей для лечения инфицированных и неинфицированных ран при сахарном диабете i типа |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |